HDAC7 and diffuse large B-cell lymphoma: Additionally, Cox univariate and multivariate survival analysis showed that high expression of HDAC7 (P = .023) combined with response therapy outcome (P = .006) was correlated with longer DSS in DLBCL patients (Table 2), confirming our previous result.